Department of Cardiology, Beijing Pinggu Hospital, Beijing, China.
Department of Cardiology, Beijing Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine, Beijing, China.
PLoS One. 2024 Aug 22;19(8):e0308719. doi: 10.1371/journal.pone.0308719. eCollection 2024.
Hyperuricemia, characterized by elevated serum uric acid levels, has garnered significant attention in cardiovascular research due to its potential association with coronary heart disease (CHD). While some studies suggest hyperuricemia as a risk factor of CHD, others present conflicting findings. A systematic review and dose-response meta-analysis is warranted to comprehensively summarize the previous studies and determine the association between hyperuricemia and CHD, thereby supporting clinical practice and future studies in this field.
In this study, we will comprehensively search Medline, EMBase, Cochrane Central, ICTRP, and ClinicalTrials.gov, from inception to December 31, 2024. Prospective or retrospective cohort studies and case-control studies investigating the association between hyperuricemia and CHD will be included. Two independent reviewers will conduct study selection, data extraction, and risk of bias assessment. The primary outcome will be the pooled relative risk of CHD associated with hyperuricemia by using random-effect model. Dose-response meta-analysis will be performed with linear and non-linear model to explore the the magnitude and direction of the association between serum uric acid levels and CHD risk. Subgroup analyses will be conducted based on uric acid test approaches and corresponding cut-off values and human races. Sensitivity analyses will assess the robustness of the results with leave-one-out method, while publication bias will be evaluated using funnel plots, Egger's test, and Begg's test. We will further use GRADE to evaluate the quality of the evidences provided by our systematic review.
From this systematic review and dose-response meta-analysis, we hope out findings will provide reliable conclusion and data support on the association between hyperuricemia and CHD. The transparent and replicable methodologies outlined in this protocol contribute to advancing understanding of hyperuricemia as a potentially modifiable risk factor for CHD, thus supporting evidence-based strategies for cardiovascular disease management.
This protocol describes a rigorous plan to systematically review and analyze the quantitative association between hyperuricemia and CHD risk. In a word, we will help further clinical practice and scientific studies in this field.
This protocol was registered in PROSPERO CRD42024538553.
高尿酸血症是指血清尿酸水平升高，由于其与冠心病（CHD）的潜在关联，在心血管研究中受到了广泛关注。虽然一些研究表明高尿酸血症是 CHD 的一个危险因素，但其他研究则提出了相互矛盾的发现。因此，有必要进行系统评价和剂量反应荟萃分析，以全面总结以往的研究结果，确定高尿酸血症与 CHD 之间的关联，从而为该领域的临床实践和未来研究提供支持。
在这项研究中，我们将全面检索 Medline、EMBase、Cochrane Central、ICTRP 和 ClinicalTrials.gov，检索时间从建库至 2024 年 12 月 31 日。将纳入前瞻性或回顾性队列研究和病例对照研究，以调查高尿酸血症与 CHD 之间的关系。两位独立的评审员将进行研究选择、数据提取和偏倚风险评估。主要结局是使用随机效应模型评估高尿酸血症与 CHD 相关的汇总相对风险。将采用线性和非线性模型进行剂量反应荟萃分析，以探讨血清尿酸水平与 CHD 风险之间的关联程度和方向。将根据尿酸检测方法和相应的截止值以及人类种族进行亚组分析。采用剔除一个研究的方法进行敏感性分析，评估结果的稳健性，同时采用漏斗图、Egger 检验和 Begg 检验评估发表偏倚。我们将进一步使用 GRADE 评估系统评价提供的证据质量。
通过这项系统评价和剂量反应荟萃分析，我们希望得出的结论和数据能够为高尿酸血症与 CHD 之间的关系提供可靠的依据。本方案中概述的透明和可重复的方法为深入了解高尿酸血症作为 CHD 一个潜在可改变的危险因素提供了支持，从而为心血管疾病管理提供了基于证据的策略。
本方案描述了一项严格的计划，旨在系统地回顾和分析高尿酸血症与 CHD 风险之间的定量关联。一言以蔽之，本方案将有助于该领域的临床实践和科学研究。
本方案已在 PROSPERO 注册，注册号为 CRD42024538553。
